Don't overlook the impact of pharma tariffs, says an analyst. Where we stand on Bristol Myers / Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance / Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug / Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs / Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs / Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint / Judge tosses Medicare drug negotiation challenges from Bristol Myers Squibb, Johnson & Johnson / Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations / Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss / Bristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharma